Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?
Kidney Transplant; Complications, Kidney Transplant Failure, Renal Failure
About this trial
This is an interventional prevention trial for Kidney Transplant; Complications focused on measuring Kidney, Transplantation, SGLT2, Renal function
Eligibility Criteria
Inclusion Criteria: Renal transplant recipients transplanted 6 weeks earlier at Oslo University hospital (OUH) Rikshospitalet. Age 18-75 years. Able to comply with the medical treatment on their own. Calcineurin inhibitor trough concentrations in accordance with individual therapeutic range and standard dose prednisolone and mycophenolate mofetil over the last 2 weeks. Estimated GFR ≥25 mL/min/1.73 m2. Exclusion Criteria: Repeat transplantation Type 1 diabetes Rejection episodes of the kidney graft prior to randomization. Ongoing infectious disease or intermittent causes affecting renal function, e.g., obstructive lymphocele. Malnutrition. Urosepsis less than 1 year prior to randomization. Participants with a known hypersensitivity to dapagliflozin or any of the excipients of the product. For women only - currently pregnant
Sites / Locations
- Oslo University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Active treatment
Control group
165 patients
165 patients